WEE1 inhibition sensitizes osteosarcoma to radiotherapy

[1]  J. Aten,et al.  In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. , 2010, Cancer cell.

[2]  A. Oza,et al.  Targeting Wee1-like protein kinase to treat cancer. , 2010, Drug news & perspectives.

[3]  G. Enders.  Gauchos and ochos: a Wee1-Cdk tango regulating mitotic entry , 2010, Cell Division.

[4]  L. Pearl,et al.  Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. , 2010, Molecular cell.

[5]  C. Beauchamp.  Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma , 2010 .

[6]  A. Unterberg,et al.  Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma , 2010, BMC Cancer.

[7]  S. Bielack,et al.  The role of radiotherapy in oseosarcoma. , 2009, Cancer treatment and research.

[8]  D. Hughes.  How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. , 2009, Cancer treatment and research.

[9]  Tsuyoshi Arai,et al.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.

[10]  T. T. Su,et al.  Tyrosines in the Kinesin-5 Head Domain Are Necessary for Phosphorylation by Wee1 and for Mitotic Spindle Integrity , 2009, Current Biology.

[11]  M. Yaffe,et al.  The combined status of ATM and p53 link tumor development with therapeutic response. , 2009, Genes & development.

[12]  D. Kirsch,et al.  Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. , 2008, International journal of radiation oncology, biology, physics.

[13]  C. Pelloski,et al.  Multimodality treatment of osteosarcoma: Radiation in a high‐risk cohort , 2008, Pediatric blood & cancer.

[14]  S. Bielack,et al.  Bone Tumors in Adolescents and Young Adults , 2008, Current treatment options in oncology.

[15]  Min-Jung Kim,et al.  Transient suppression of nuclear Cdc2 activity in response to ionizing radiation. , 2008, Oncology reports.

[16]  C. Herzog,et al.  Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). , 2008, Expert opinion on investigational drugs.

[17]  P. Anderson,et al.  Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[18]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[19]  H. Koga,et al.  Cell cycle regulation by the Wee1 Inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line , 2006, BMC Cancer.

[20]  L. Meijer,et al.  Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. , 2006, Cancer research.

[21]  J. Bartek,et al.  Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. , 2006, Cancer research.

[22]  B. Hoang,et al.  Osteosarcoma: basic science and clinical implications. , 2006, The Orthopedic clinics of North America.

[23]  P. Anderson,et al.  Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma , 2005, Clinical Cancer Research.

[24]  T. Delaney,et al.  Radiotherapy for local control of osteosarcoma. , 2003, International journal of radiation oncology, biology, physics.

[25]  Guido Kroemer,et al.  Cell death by mitotic catastrophe: a molecular definition , 2004, Oncogene.

[26]  T. Kawabe.  G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.

[27]  P. Meltzer,et al.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  P. Anderson.  Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. , 2003, Mayo Clinic proceedings.

[29]  G. Machak,et al.  Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. , 2003, Mayo Clinic proceedings.

[30]  T. Weinert,et al.  Toward maintaining the genome: DNA damage and replication checkpoints. , 2002, Annual review of genetics.

[31]  Susumu Kandatsu,et al.  Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jun Yu Li,et al.  Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. , 2001, Cancer research.

[34]  J. Raleigh,et al.  The G(2) DNA damage checkpoint targets both Wee1 and Cdc25. , 2000, Journal of cell science.

[35]  T. Tokusumi,et al.  The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. , 1999, Journal of cell science.